Table of contents

  1. Front Matter
    Pages I-XXII
  2. Mechanic Approaches to CNS Neuroprotection

    1. Front Matter
      Pages 1-1
    2. A. H. Kim, G. A. Kerchner, D. W. Choi
      Pages 3-36
    3. K. J. Becker, J. M. Hallenbeck
      Pages 65-93
    4. M. P. Mattson
      Pages 115-153
    5. M. Sasaki, T. M. Dawson, V. L. Dawson
      Pages 155-173
  3. Neuroprotective Agents

  4. CNS Delivery of Neuroprotective Therapies

    1. Front Matter
      Pages 299-299
    2. A. Blesch, M. H. Tuszynski
      Pages 301-333
  5. Disease Targeting of Neuroprotective Therapies

About this book


"CNS neuroprotection" was a common subject of papers, symposia, and reviews during the previous "decade of the brain. " Indeed, in recent years, experimental study of putative neuroprotective agents prompted clinical trials of numerous drug candidates in acute and chronic human neurodegenerative conditions. While the outcomes of these trials have not been as successful as initially hoped, these were early explorations, and the pipeline of relevant ideas continues to grow in strength and depth. We predict that early in this new millennium, crippling disorders such as stroke and Alzheimer's disease will be treated effectively by therapeutic neuroprotective strategies. This volume of the Handbook of Experimental Pharmacology titled eNS Neuroprotection provides a pharmacological perspective on currently promis­ ing neuroprotective approaches, and a clinical perspective on the challenges involved in establishing the efficacy of these approaches through appropriate clinical trials. Section I, "Mechanistic Approaches to CNS Neuroprotection," reviews major injury mechanisms that have formed the basis for many past and present clinical trials conducted around the world. Dr. KIM and colleagues, Washington University School of Medicine, review the status of blocking excitotoxicity as an approach to CNS neuroprotection. Dr. WANG, Pfizer Global Research and Development,Ann Arbor Laboratories, outlines evidence supporting a contri­ bution of apoptosis to pathological neuronal or glial cell loss. Drs. BECKER and HALLENBECK, University of Washington and the National Institute on Neuro­ logical Diseases and Stroke, respectively, argue that inhibiting inflammatory pathways in the brain can be neuroprotective. Dr.


Central Nervous System Chemokine Gentherapie Nervous System Neurodegenerative Disease Neuropharmakologie Neuroprotection Neurotoxität Stroke Zentralnervensystem adenosine gene therapy genes

Editors and affiliations

  • Frank W. Marcoux
    • 1
  • Dennis W. Choi
    • 2
  1. 1.Pfizer Global Research and DevelopmentAnn Arbor LaboratoriesAnn ArborUSA
  2. 2.Department of Neurology Box 8111Washington University School of MedicineSt. LouisUSA

Bibliographic information

  • Book Title CNS Neuroprotection
  • Editors Frank W. Marcoux
    Dennis W. Choi
  • Series Title Handbook of Experimental Pharmacology
  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2002
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Hardcover ISBN 978-3-540-42412-3
  • Softcover ISBN 978-3-642-07625-1
  • eBook ISBN 978-3-662-06274-6
  • Series ISSN 0171-2004
  • Series E-ISSN 1865-0325
  • Edition Number 1
  • Number of Pages XXII, 500
  • Number of Illustrations 78 b/w illustrations, 5 illustrations in colour
  • Topics Pharmacology/Toxicology
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods